Statins in liver disease: A molehill, an iceberg, or neither?

Hepatology

Volumn 48, Issue 2, 2008, Pages 662-669

  Argo, Curtis K ^a   Loria, Paola ^b   Caldwell, Stephen H ^a   Lonardo, Amedeo ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; HEPATITIS C; HUMAN; LIPID METABOLISM; LIPID PEROXIDATION; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER METABOLISM; LONG TERM CARE; LOW DRUG DOSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CARDIOVASCULAR DISEASES; CHOLESTEROL; FATTY LIVER; HEPATITIS C; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; LIVER DISEASES; LIVER NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 49649106710     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22402     Document Type: Review

References (96)

1. Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question. Nutr Metab Cardiovasc Dis 2007;17:684-698.
2. Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007; 46:1126-1132.
3. Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002;51:265-269.
4. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;128:1287-1292.
5. Liberopoulos EN, Athyros VG, Elisaf MS, Mikhailidis DP. Statins for non-alcoholic fatty liver disease: A new indication? Aliment Pharmacol Ther 2006;24:698-699.
6. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
7. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: A meta-analysis. Pharmacotherapy 2004;24:584-591.
8. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease. HEPATOLOGY 2007;46: 1453-1463.
9. Grundy SM, Cleeman JI, Metz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
10. Jasińska M, Owczarek J, Orszulak-Michalak D. Statins: A new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007;59:483-499.
11. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344: 1959-1965.
12. Targher G. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. J Hepatol 2006;45:879-882.
13. Oberti F, Pilette C, Rifflet H, Maïga MY, Moreau A, Gallois Y, et al. Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol 1997;26: 1363-1371.
14. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. HEPATOLOGY 2007;46:242-253.
15. Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernández M, Garca-Pagán JC, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004;126:749-755.
16. Prabhakar YS, Saxena AK, Doss MJ. QSAR study of the role of hydrophobicity in the activity of HMGR inhibitors. Drug Des Deliv 1989;4:97-108.
17. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharmacol Ther 2006;112:71-105.
18. Dale KM, White CM, Henyan NN, Kluger J, Coleman CI. Impact of statin dosing intensity on transaminase and creatine kinase. Am J Med 2007;120:706-712.
19. Zhou Z, Rahme E, Pilote L. Are statins created equal? Am Heart J 2006; 151:273-281.
20. Paoletti R, Bolego C, Cignarella A. Lipid and non-lipid effects of statins. Handb Exp Pharmacol 2005;170:365-388.
21. Resch U, Tatzber F, Budinsky A, Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 2006;61:262-274.
22. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:1497-1502.
23. Thallinger C, Urbauer E, Lackner E, Graselli U, Kostner K, Wolzt M, et al. The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients. Int J Clin Pharmacol Ther 2005;43:551-557.
24. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006;116:607-614.
25. Habeos I, Ziros PG, Psyrogiannis A, Vagenakis AG, Papavassiliou AG. Statins and transcriptional regulation: The FXR connection. Biophys Res Comm 2005;334:601-605.
26. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-1131.
27. Browning JD. Statins and hepatic steatosis: Perspectives from the Dallas Heart Study. HEPATOLOGY 2006;44:466-471.
28. Scharnagl H, Schinker R, Gierens H, Nauck M, Wieland H, März W. Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol 2001;62:1545-1555.
29. Tamehiro N, Shigemoto-Mogami Y, Kakeya T, Okuhira K, Suzuki K, Sato R, et al. Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression. J Biol Chem 2007;282:21090-21099.
30. Canbay A, Bechmann L, Gerken G. Lipid metabolism in the liver. Z Gastroenterol 2007,45:35-41.
31. van der Leij FR, Bloks VW, Grefhorst A, Hoekstra J, Gerding A, Kooi K, et al. Gene expression profiling in livers of mice after acute inhibition of beta-oxidation. Genomics 2007;90:680-689.
32. Loria P, Bertolotti M, Cassinadri MT, Dilengite MA, Bozzoli M, Carubbi F, et al. Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects. HEPATOLOGY 1994;19:882-888.
33. Bertolotti M, Abate N, Loria P, Dilengite M, Carubbi F, Pinetti A, et al. Regulation of bile acid synthesis in humans: Effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7 alpha-hydroxylation rates in vivo. HEPATOLOGY 1991;14:830-837.
34. Hillebrant CG, Nyberg B, Gustafsson U, Sahlin S, Björkhem I, Rudling M, et al. Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism. Ent J Clin Invest 2002;32: 528-534.
35. Claudel T, Staels B, Kuipers F. The farnesoid X receptor: A molecular link between bile acid and lipid and glucose metabolism. Arterioscl Thromb Vasc Biol 2005;25:2020-2030.
36. Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J 2006;25:1419-1425.
37. Kobayashi M, Ikegami H, Fujisawa T, Nojima K, Kawabata Y, Noso S, et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007;56:239-247.
38. Theise ND, Kuwahara R. The tissue biology of ductular reactions in human chronic liver disease. Gastroenterology 2007;133:350-352.
39. Bubman KK, Wang LC, Tang Y, Swietlicki EA, Kennedy S, Xie Y, et al. Inhibition of hedgehog signaling protects adult mice from diet-induced weight gain. J Nutr 2004;134:2979-2984.
40. Yang L, Wang Y, Mao H, Fleig S, Omenetti A, Brown KD, et al. Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J Hepatol 2008;48:98-106.
41. Loria P, Lonardo A, Carulli L, Verrone AM, Ricchi M, Lombardini S, et al. The metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2005;22(Suppl 2):31-36.
42. Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome. Prevalence and determinants of a "bright" liver echopattern. Ital J Gastroenterol Hepatol 1997;29:351-356.
43. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. HEPATOLOGY 2004;40:1387-1395.
44. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. HEPATOLOGY 2005;42:473-480.
45. Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008;121:72-78.
46. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999;22:756-761.
47. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262-265.
48. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. HEPATOLOGY 2006;44:865-873.
49. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999;354:141-148.
50. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 2007;100:1442-1451.
51. Sanguino E, Roglans N, Alegret M, Sánchez RM, Vázquez-Carrera M, Laguna JC. Atorvastatin reverses age-related reduction in hepatic PPARalpha and HNF-4. Br J Pharmacol 2005; 145:853-861.
52. Koter M, Broncel M, Chojnowska-Jezierska J, Klikczynska K, Franiak I. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia. Ent J Clin Pharmacol 2002;58: 501-506.
53. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-362.
54. Ishikawa M, Namiki A, Kubota T, Yajima S, Fukazawa M, Moroi M, et al. Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. Intern Med 2006;45:51-55.
55. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? HEPATOLOGY 2004;40:46-54.
56. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steamhepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroemetol 2007;42:573-582.
57. Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P. Hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 2005;22(Suppl 2):64-70.
58. Sugiyama S, Fukushima H, Kugiyama K, Maruyoshi H, Kojima S, Funahashi T, et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007;194:e43-e5l
59. Satoh T, Isobe H, Ayukawa K, Sakai H, Nawata H. The effects of pravastatin, an HMG-CoA reductase inhibitor, on cell viability and DNA production of rat hepatocytes. Life Sci 1996;59:1103-1108.
60. Velho JA, Okanobo H, Degasperi GR, Matsumoto MY, Alberici LC, Cosso RG, et al. Statins induce calcium-dependent mitochondrial permeability transition. Toxicology 2006;219:124-132.
61. Pääjärvi G, Roudier E, Crisby M, Högberg J, Stenius U. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB, J 2005;19:476-478.
62. Moore DD, Kato S, Xie W, Mangelsdorf DJ, Schmidt DR, Xiao R, et al. The NR1H and NR1I receptors: Constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, famesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol Rev 2006;58:742-759.
63. Kobayashi K, Yamanaka Y, Iwazaki N, Nakajo I, Hosokawa M, Negishi M, et al. Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos 2005;33:924-929.
64. Rombouts K, Kisanga E, Hellemans K, Wielant A, Schuppan D, Geerts A. Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol 2003;38:564-572.
65. Zhao A, Yu J, Lew JL, Huang L, Wright SD, Cui J. Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets. DNA Cell Biol 2004;23:519-526.
66. Horlander J, Kwo P, Cummings O. Atorvastatin for the treatment of NASH. Gastroenterology 2001;120:A544.
67. Kiyici M, Golten M, Gurel S, Nak SG, Dolar E, Savci G, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003;17:713-718.
68. Rallidis L, Drakoulis C, Parasi A. Pravastatin in patients with nonalcoholic steatohepatitis: Results of a pilot study. Atherosclerosis 2004;174:193-196.
69. Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulos A, et al. Efficacy of omega-3 fatty acids, atorvastatin, and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004;23:131-134.
70. Gómez-Domínguez E, Gisbert JP, Moreno-Monteaguclo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006;23:1643-1647.
71. Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of nonalcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006;184:233-234.
72. Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study. J Hepatol 2007;47:135-141.
73. Lonardo A, Loria P, Carulli N. Dysmetabolic changes associated with HCV: a distinct syndrome? Intern Emerg Med 2008;3:99-108.
74. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, et al. Genotype-specific mechanisms for hepatic stearosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002;17:873-881.
75. Fernández-Rodríguez CM, López-Serrano P, Alonso S, Gutiérrez ML, Lledó JL, Pérez-Calle JL, et al. Long-term reversal of hypocholesterolaemia in patients with chronic hepatitis C is related to sustained viral response and viral genotype. Aliment Pharmacol Ther 2006;24:507-512.
76. Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. HEPATOLOGY 2006;44:335-340.
77. Aizaki H, Lee KJ, Sung VM, Ishiko H, Lai MM. Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology 2004;324:450-461.
78. Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005; 102:2561-2566.
79. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. HEPATOLOGY 2006;44:117-125.
80. Brown MS, Goldstein JL. Lowering plasma cholesterol by raising LDL receptors. N EngI J Med 1981;305:515-517.
81. Monazahian M, Böhme I, Bonk S, Koch A, Scholz C, Grethe S, et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999;57:223-229.
82. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-597.
83. O'Leary JG, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trial. HEPATOLOGY 2007;45:895-898.
84. Del Puppo M, Galli Kienle M, Crosignani A, Petroni ML, Amati B, Zuin M, et al. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration. J Lipid Res 2001;42:437-441.
85. Ritzel U, Leonhardc U, Näther M, Schäfer G, Armstrong VW, Ramadori G. Simvastatin in primary biliary cirrhosis: Effects on serum lipids and distinct disease markers. J Hepatol 2002;36:454-458.
86. Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. HEPATOLOGY 2007;46:776-784.
87. Kusuyama T, Omura T, Nishiya D, Enomoto S, Matsumoto R, Takeuchi K, et al. The effects of HMG-CoA reductase inhibitor on vascular progenitor cells. J Pharmacol Sci 2006;101:344-349.
88. Skaletz-Rorowski A, Kureishi Y, Shiojima I, Walsh K. The pro- and anti-angiogenic effects of statins. Semin Vasc Med 2004;4:395-400.
89. Katsumoto M, Shingu T, Kuwashima R, Nakata A, Nomura S, Chayama K. Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J 2005;69:1547-1555.
90. Muck AO, Seeger H, Wallwiener D. Class-specific pro-apoptotic effect of statins on human vascular endothelial cells. Z Kardiol 2004;93:398-402.
91. Takahashi HK, Weitz-Schmidt G, Iwagaki H, Yoshinc, T, Tanaka N, Nishibori M. Hypothesis: The antitumor activities of statins may be mediated by IL- 18. J Leukoc Biol 2006;80:215-216.
92. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002; 91:143-150.
93. Brouer A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, Peron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 2001;89:866-873.
94. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-1010.
95. Lersch C, Schmelz R, Erdmann J, Hollweck R, Schulte-Frohlinde E, Eckel F, et al. Treatment of HCC with pravastatin, octreotide, or gemcitabine - a critical evaluation. Hepatogastroenterology 2004;51:1009-1013.
96. El-Serag H, Johnson M, Kuebler M, Morgan R. Statin use and risk of hepatocellular carcinoma. Gastroenterology 2007;132(Suppl 2):56.